GW Pharma soars as cannabis drug succeeds in epilepsy trial

LONDON (Reuters) - An experimental cannabis-based drug has successfully treated children with a rare form of severe epilepsy in a keenly anticipated clinical trial, sending shares in its maker GW Pharmaceuticals 68 percent higher on Monday.